0
Correspondence |

Dermatitis to FD &C Yellow No. 6 Dye in Orange Antiseptic Solution

Patrick E. McCleskey, MD
[+] Author Affiliations

Author Affiliation: Department of Dermatology, David Grant Medical Center, Travis Air Force Base, California.


Arch Dermatol. 2011;147(9):1124-1125. doi:10.1001/archdermatol.2011.245
Text Size: A A A
Published online
Figures in this Article

REPORT OF A CASE

A 25-year-old white man was referred for an intensely pruritic erythematous papular and vesicular eruption on his right forearm (Figure 1A) that began several days after placement of a long arm plaster cast after an open reduction and internal fixation for a right ulnar styloid fracture. An orange hue could be seen under the cotton in his cast (Figure 1B). The only antiseptic that had been used during the surgery was Hi-Lite Orange ChloraPrep (CareFusion, Leawood, Kansas); tincture of benzoin was not used. The eruption resolved with application of triamcinolone acetonide, 0.1%, ointment before recasting the arm.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Clinical images. A, Vesicular eruption 2 weeks after surgery. B, Inside of cast showing orange hue from Hi-Lite Orange ChloraPrep (CareFusion, Leawood, Kansas).

ChloraPrep is an antiseptic containing isopropyl alcohol, 70%, chlorhexidine gluconate, 2%, and purified water; Hi-Lite Orange ChloraPrep is identical except that it also contains Federal Food, Drug, and Cosmetic Act (FD &C) yellow No. 6 dye (proprietary amount)1 in a polyester pledget through which the alcohol and chlorhexidine mixture flows. Patch testing was performed with the 29-allergen T.R.U.E. Test (SmartPractice, Phoenix, Arizona), as well as the ChloraPrep with and without orange tint, in standard patch testing and open application testing on bilateral forearms. The only allergen on the T.R.U.E. test to provoke a positive reaction was balsam of Peru (Myroxylon pereirae resin), 2+ reaction at 96 hours. Open application testing of ChloraPrep with orange tint showed a 2+ reaction at 48 and 96 hours, but the ChloraPrep without tint was nonreactive (Figure 2). Standard patch testing showed a 1+ reaction for ChloraPrep with orange tint and no reaction for Chloraprep without tint. Open application testing of the ChloraPrep with orange tint was performed in 10 volunteers; all were nonreactive.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Forearms after 4 days of open application of Hi-Lite Orange ChloraPrep (CareFusion, Leawood, Kansas) to the right arm (left) and ChloraPrep without orange tint to the left arm (right).

COMMENT

The combination of alcohol and chlorhexidine is used perioperatively because it is associated with lower positive culture rates than povidone-iodine or iodine plus alcohol.2 A representative from the manufacturer reported that the irritation rate to ChloraPrep is less than 1%, but eruptions have occurred after breast and orthopedic surgical procedures, presumably increased by the immediate occlusive dressings or casts (Amy Taitt, RN, e-mail communication, April 24, 2009). The Material Safety Data Sheet for ChloraPrep with orange tint states that “prolonged contact may cause dermatitis. ”1 Allergic contact dermatitis to chlorhexidine is rare but has been reported3 ; that possibility is excluded in this case by the lack of reaction to the ChloraPrep without tint.

Federal Food, Drug, and Cosmetic Act yellow No. 6 dye is an azo dye that is also called Sunset Yellow FCF (CI 15985), E110, or disodium 6-hydroxy-5-[(4-sulfophenyl)azo]-2-naphthalenesulfononate. Allergic contact dermatitis to FD &C yellow No. 6 dye has rarely been reported; Guin4 patch tested 144 patients to FD &C yellow No. 6 dye and found 4 positive reactions. A commercial patch test to FD &C yellow No. 6 dye is not available, but patch test studies of other yellow dyes show high concentrations may be needed and that test results may not be reproducible over time.5 - 6 Federal Food, Drug, and Cosmetic Act yellow No. 6 dye has been associated with gastroenteritis, asthma, urticaria, and anaphylactoid reactions.7 - 8

It appears that this patient had an allergic contact dermatitis to FD &C yellow No. 6 dye. It is possible that the occlusion following orthopedic surgery creates a condition under which this arises. Inactive ingredients can be a cause of many ailments including contact dermatitis.8 - 9

AUTHOR INFORMATION

Correspondence: Dr McCleskey, Maj, USAF, MC, Department of Dermatology, David Grant Medical Center, 101 Bodin Circle, Travis Air Force Base, CA 94535 (Patrick.mccleskey@us.af.mil).

Financial Disclosure: None reported.

Disclaimer: The views expressed in this material are those of Dr McCleskey and do not reflect the official policy or position of the US government, the Department of Defense, or the Department of the Air Force.

Additional Contribution: Jerri Hoskins, MD, provided information about Guin's study4 on FD &C dyes.

REFERENCES

CareFusion.  Material Safety Data Sheet for ChloraPrep. http://www.chloraprep.com/safety-information. Accessed December 29, 2010
Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery.  J Bone Joint Surg Am. 2009;91(8):1949-1953
PubMedCrossRef
Osmundsen PE. Contact dermatitis to chlorhexidine.  Contact Dermatitis. 1982;8(2):81-83
PubMedCrossRef
Guin JD. Patch testing to FD &C and D &C dyes.  Contact Dermatitis. 2003;49(4):217-218
PubMedCrossRef
Rapaport MJ. Allergy to yellow dyes.  Arch Dermatol. 1984;120(4):535-536
PubMedCrossRef
Dinardo J, Draelos ZD. An animal model assessment of common dye-induced allergic contact dermatitis.  J Cosmet Sci. 2007;58(3):209-214
PubMed
Gross PA, Lance K, Whitlock RJ, Blume RS. Additive allergy: allergic gastroenteritis due to yellow dye #6.  Ann Intern Med. 1989;111(1):87-88
PubMed
American Academy of Pediatrics Committee on Drugs.   “Inactive ” ingredients in pharmaceutical products: update (subject review).  Pediatrics. 1997;99(2):268-278
PubMedCrossRef
Ritter SE, Meffert JM. A refractory fixed drug reaction to a dye used in an oral contraceptive.  Cutis. 2004;74(4):243-244
PubMed

First Page Preview

First page PDF preview

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Clinical images. A, Vesicular eruption 2 weeks after surgery. B, Inside of cast showing orange hue from Hi-Lite Orange ChloraPrep (CareFusion, Leawood, Kansas).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Forearms after 4 days of open application of Hi-Lite Orange ChloraPrep (CareFusion, Leawood, Kansas) to the right arm (left) and ChloraPrep without orange tint to the left arm (right).

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

CareFusion.  Material Safety Data Sheet for ChloraPrep. http://www.chloraprep.com/safety-information. Accessed December 29, 2010
Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery.  J Bone Joint Surg Am. 2009;91(8):1949-1953
PubMedCrossRef
Osmundsen PE. Contact dermatitis to chlorhexidine.  Contact Dermatitis. 1982;8(2):81-83
PubMedCrossRef
Guin JD. Patch testing to FD &C and D &C dyes.  Contact Dermatitis. 2003;49(4):217-218
PubMedCrossRef
Rapaport MJ. Allergy to yellow dyes.  Arch Dermatol. 1984;120(4):535-536
PubMedCrossRef
Dinardo J, Draelos ZD. An animal model assessment of common dye-induced allergic contact dermatitis.  J Cosmet Sci. 2007;58(3):209-214
PubMed
Gross PA, Lance K, Whitlock RJ, Blume RS. Additive allergy: allergic gastroenteritis due to yellow dye #6.  Ann Intern Med. 1989;111(1):87-88
PubMed
American Academy of Pediatrics Committee on Drugs.   “Inactive ” ingredients in pharmaceutical products: update (subject review).  Pediatrics. 1997;99(2):268-278
PubMedCrossRef
Ritter SE, Meffert JM. A refractory fixed drug reaction to a dye used in an oral contraceptive.  Cutis. 2004;74(4):243-244
PubMed

Correspondence

CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles